News
UNCY
6.93
-2.67%
-0.19
Unicycive Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 2d ago
Unicycive Therapeutics Price Target Cut to $40.00/Share From $46.00 by Guggenheim
Dow Jones · 2d ago
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40
Benzinga · 2d ago
Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Reuters · 2d ago
UNICYCIVE THERAPEUTICS INC <UNCY.O>: GUGGENHEIM CUTS TARGET PRICE TO $40 FROM $46
Reuters · 2d ago
Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date
Reuters · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Unicycive Therapeutics (UNCY), Biomea Fusion (BMEA)
TipRanks · 4d ago
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)
TipRanks · 4d ago
Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate
Benzinga · 5d ago
Unicycive Therapeutics presentation highlights OLC NDA review for dialysis hyperphosphatemia treatment
Reuters · 5d ago
Unicycive Therapeutics GAAP EPS of -$1.67 misses by $0.02
Seeking Alpha · 5d ago
Press Release: Unicycive Therapeutics Announces -2-
Dow Jones · 5d ago
Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Dow Jones · 5d ago
Weekly Report: what happened at UNCY last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at UNCY last week (0316-0320)?
Weekly Report · 03/23 09:38
3 Best Stocks to Buy Today, 3/18/2026, According to Top Analysts
TipRanks · 03/18 12:50
Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
TipRanks · 03/18 10:15
Weekly Report: what happened at UNCY last week (0309-0313)?
Weekly Report · 03/16 09:37
Weekly Report: what happened at UNCY last week (0302-0306)?
Weekly Report · 03/09 09:39
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.